|
Eosinophilic esophagitis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.
|
25017104 |
2014 |
|
Neuralgia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Purinergic receptor P2Y<sub>12</sub> (P2Y<sub>12</sub> ), a G protein-coupled purinergic receptor, is widely distributed in nervous system and involved in the progression of neurological diseases such as multiple sclerosis and neuropathic pain.
|
29341465 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The effects of purinergic receptor stimulation or agonism tend to produce inflammatory responses that may aid immune stimulation but may also provoke various immune suppression mechanisms, particularly in the tumor microenvironment.
|
30209547 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Preclinical studies in several tumour models have shown that P2X7R targeting is potentially a very effective anticancer treatment, and many pharmaceutical companies have now developed potent and selective small molecule inhibitors of P2X7R.
|
30006588 |
2018 |
|
Neuralgia
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The present study demonstrated that dexmedetomidine attenuates the neuropathic pain induced by CCI of the sciatic nerve in rats by inhibiting spinal P2X7R expression and ERK phosphorylation, indicating the potential therapeutic implications of dexmedetomidine administration for the treatment of neuropathic pain.
|
30181689 |
2018 |
|
Neuralgia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We based this hypothesis on evidence that microglia preferentially contribute to neuropathic pain in male mice via ionotropic purinergic receptor (P2XR) or p38 mitogen-activated protein kinase (p38) signaling.
|
29913243 |
2018 |
|
Neuralgia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
A role for the purinergic receptor P2X<sub>3</sub> in astrocytes in the mechanism of craniofacial neuropathic pain.
|
29051582 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These results suggest that the efficacy of BBG in inhibiting tumor growth is primarily mediated by direct actions of the compound on P2X7R in glioma cells and that pharmacological inhibition of this purinergic receptor might serve as a strategy to slow the progression of brain tumors.
|
21157381 |
2011 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We also looked for p53 mutations and mdm2 overexpression in the same panel of tumours and found them in 13 tumours, all but three of which had shown altered expression of P2XM.
|
10376970 |
1999 |
|
Narcolepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association analysis shows a strong association between narcolepsy and polymorphisms in the TCRα locus and weaker associations within TNFSF4 (also called OX40L), Cathepsin H and the P2RY11-DNMT1 (purinergic receptor subtype P2Y11 to DNMT1, a DNA methytransferase) loci, suggesting an autoimmune basis.
|
23497937 |
2013 |
|
Narcolepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide association studies have strengthened the association between narcolepsy and immune system gene polymorphisms, including the identification of polymorphisms in the T cell receptor alpha locus, TNFSF4 (also called OX40L), Cathepsin H (CTSH) the purinergic receptor P2RY11, and the DNA methyltransferase DNMT1.
|
23725858 |
2013 |
|
Narcolepsy
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We identify a SNP in the 3' untranslated region of P2RY11, the purinergic receptor subtype P2Y₁₁ gene, which is associated with narcolepsy (rs2305795, combined P = 6.1 × 10⁻¹⁰, odds ratio = 1.28, 95% CI 1.19-1.39, n = 5689).
|
21170044 |
2011 |
|
Heart failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a significant putative HCM causative gene, P2X7, for the first time and show that germ-line mutations in P2X7 may cause a defective phenotype, suggesting purinergic receptor involvement in heart failure mediated through arrhythmias which need further investigations to be targeted for therapeutic interventions.
|
31152337 |
2019 |
|
Congestive heart failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a significant putative HCM causative gene, P2X7, for the first time and show that germ-line mutations in P2X7 may cause a defective phenotype, suggesting purinergic receptor involvement in heart failure mediated through arrhythmias which need further investigations to be targeted for therapeutic interventions.
|
31152337 |
2019 |
|
Multiple Sclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the neuroinflammatory foci of MS there is increased expression of a purinergic receptor, P2X7R.
|
30908981 |
2019 |
|
Multiple Sclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Purinergic receptor P2Y<sub>12</sub> (P2Y<sub>12</sub> ), a G protein-coupled purinergic receptor, is widely distributed in nervous system and involved in the progression of neurological diseases such as multiple sclerosis and neuropathic pain.
|
29341465 |
2019 |
|
Parkinson Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Modulation of purinergic receptor subtypes, the activity of ectonucleotidases and ATP transporters could be beneficial in the treatment of PD.
|
31054067 |
2019 |
|
Endothelial dysfunction
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These data suggest that endothelial dysfunction caused by exposure to acidic, non-buffered NS is associated with loss of membrane integrity, release of ATP, and is modulated by P2X7R-mediated inflammatory responses.
|
31412063 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Cutaneous vascular conductance and sweat rate were evaluated in 12 healthy non-diabetic older adults (Control, 60 ± 8 years) and 13 older adults with T2D (62 ± 10 years) at three intradermal forearm skin sites perfused with the following: (i) methacholine (muscarinic receptor agonist, five doses: 0.0125, 0.25, 5, 100 and 2000 mm); (ii) nicotine (nicotinic receptor agonist, five doses: 1.2, 3.6, 11, 33 and 100 mm); or (iii) ATP (purinergic receptor agonist, five doses: 0.03, 0.3, 3, 30 and 300 mm).
|
29210478 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altered Purinergic Receptor Sensitivity in Type 2 Diabetes-Associated Endothelial Dysfunction and Up₄A-Mediated Vascular Contraction.
|
30544633 |
2018 |
|
Osteopenia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purinergic receptor P2X5 contributes to bone loss in experimental periodontitis.
|
30103845 |
2018 |
|
Parkinson Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In neurological disorders with associated motor symptoms, including Parkinson's disease (PD), motor neuron diseases (MND), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington's Disease (HD), restless leg syndrome (RLS), and ataxias, alterations in purinergic receptor expression and activity have been noted, indicating a potential role for this system in disease etiology and progression.
|
29692728 |
2018 |
|
Autosomal Recessive Polycystic Kidney Disease
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Characterization of purinergic receptor expression in ARPKD cystic epithelia.
|
30417216 |
2018 |
|
Chronic pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In mice and humans, the release of eATP during inflammation or injury stimulates both innate immune activation and chronic pain through the purinergic receptor P2RX7<sup>2-4</sup>.
|
29973721 |
2018 |
|
Mood Disorders
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Various studies have investigated whether single nucleotide polymorphisms (SNPs) in the gene purinergic receptor P2X7 (P2RX7), and rs2230912 specifically, were associated with mood disorders.
|
29122639 |
2018 |